INCR - InterCure: A Cannabis Industry Leader Still Flying Under The Radar

2024-06-30 03:42:20 ET

Summary

• InterCure is a leading pharmaceutical/medical cannabis company based in Israel and a global leader outside North America.
• Despite the damage the Hamas attack and the state of war in Israel caused, the company managed to sustain operations and present a positive 2023 ER.
• The company is entitled to full compensation from the Israeli government for the damage taken.
• Pharmaceutical Cannabis industry is poised for significant growth in the coming years.
• InterCure stock should be considered poorly valued.

Investing Thesis

InterCure ( INCR ), a leading pharmaceutical/medical cannabis company based in Israel, and a global leader outside North America, has been hit hard by the Hamas attack and the war that followed and so has its stock. Despite these facts, the company managed to sustain operations and present positive 2023 results ; the stock price also started recovering after market overreaction. While having the support of the state of Israel during this difficult situation, the company unfolds its profitable growth prospect and plans its international expansion. Furthermore, the pharmaceutical cannabis industry is poised for significant growth in the coming years. Therefore, investors should benefit from a stock price correction and initiate a position....

For further details see: